A device impregnated with a hemostatic composition, wherein the hemostatic composition comprises: two hemostatic agents, at least one in a form having a dimension less than one micron, wherein the hemostatic agents are in combination with a surfactant in an effective amount to reduce bleeding, increase clotting, or a combination thereof when applied to a carrier or device and contacted with a wound or hemorrhage on a subject; wherein the surfactant is present in an effective amount to increase stability, enhance disbursement, or increase the surface area of one of the two hemostatic agents; wherein the surfactant is in the form of a nanoparticle as a micelle; wherein the device is a non-woven gauze, and the none woven-gauze is impregnated with the hemostatic composition comprising: the hemostatic agents kaolin and chitosan, the surfactant Pluronic ® F-127, and additionally, glycerin; wherein the Pluronic ® F-127 that is prepared in the form of nanoparticles is configured to stabilize the kaolin, whereas the chitosan is included in the form of nanofibers, wherein the total amount of the hemostatic agents is 50% of the total weight of the device and Pluronic ® F-127 is 5% of the total weight of the device; wherein the chitosan micro- and nano-hased fibers have diameters of 2.4 ± 0.9 μm and 101 ± 56 nm, respectively. two hemostatic agents, at least one in a form having a dimension less than one micron, wherein the hemostatic agents are in combination with a surfactant in an effective amount to reduce bleeding, increase clotting, or a combination thereof when applied to a carrier or device and contacted with a wound or hemorrhage on a subject; wherein the surfactant is present in an effective amount to increase stability, enhance disbursement, or increase the surface area of one of the two hemostatic agents; wherein the surfactant is in the form of a nanoparticle as a micelle; wherein the device is a non-woven gauze, and the none woven-gauze is impregnated with the hemostatic composition comprising: the hemostatic agents kaolin and chitosan, the surfactant Pluronic ® F-127, and additionally, glycerin; wherein the Pluronic ® F-127 that is prepared in the form of nanoparticles is configured to stabilize the kaolin, whereas the chitosan is included in the form of nanofibers, wherein the total amount of the hemostatic agents is 50% of the total weight of the device and Pluronic ® F-127 is 5% of the total weight of the device; wherein the chitosan micro- and nano-hased fibers have diameters of 2.4 ± 0.9 μm and 101 ± 56 nm, respectively. the hemostatic agents kaolin and chitosan, the surfactant Pluronic ® F-127, and additionally, glycerin; wherein the Pluronic ® F-127 that is prepared in the form of nanoparticles is configured to stabilize the kaolin, whereas the chitosan is included in the form of nanofibers, wherein the total amount of the hemostatic agents is 50% of the total weight of the device and Pluronic ® F-127 is 5% of the total weight of the device; wherein the chitosan micro- and nano-hased fibers have diameters of 2.4 ± 0.9 μm and 101 ± 56 nm, respectively. wherein the Pluronic ® F-127 that is prepared in the form of nanoparticles is configured to stabilize the kaolin, whereas the chitosan is included in the form of nanofibers, wherein the total amount of the hemostatic agents is 50% of the total weight of the device and Pluronic ® F-127 is 5% of the total weight of the device; wherein the chitosan micro- and nano-hased fibers have diameters of 2.4 ± 0.9 μm and 101 ± 56 nm, respectively.